News. Analysis. Insight.™ - 100 Years of Journalistic Excellence

Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company engaged in developing therapies that target the molecular mechanisms that cause cancer. With the Company’s collaborators, the Company is developing anticancer therapies. The Company’s product, Nexavar (sorafenib) tablets, being developed with the Company’s collaborator Bayer HealthCare Pharmaceuticals (Bayer), is approved by the United States Food and Drug Administration (FDA), for advanced kidney cancer and liver cancer. Nexavar is an orally available kinase and angiogenesis inhibitor and is one of a new class of anticancer treatments that target both cancer cell proliferation and tumor growth through the inhibition of key signaling pathways. As of December 31, 2008, Nexavar was approved in more than 70 countries for the treatment of advanced kidney cancer and in more than 60 countries for the treatment of liver cancer.

Industry	Health
Sector	Biotechnology
# of Employees	125
Shares Outstanding	62.1M
Market Cap	1.9B
Enterprise Value	973.2M

52-Week High	$37.02
52-Week Low	$21.85
P/E Ratio	-176.71
EPS	-$0.17/shr
Dividend	-
Yield	-

N. Anthony Coles

C.E.O., Pres., Dir.

Matthew K. Fust

C.F.O., Exec. V.P., Principal Accounting Officer

Laura A. Brege

C.O.O., Exec. V.P.

Paul Goddard

Lead Director

Juergen Lasowski

Sr. V.P. - Corp. Development

Julianna R. Wood

V.P. - Corporate Communications & Investor Relations

Judy A. Batlin

V.P. - Organizational Learning, Development & Human Resources

Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Stock News provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs